STAT

JULY 14, 2023

Limbix recently completed a pivotal clinical trial of its depression treatment, SparkRx, and also has an early-stage product in development to treat adolescent anxiety. Continue to STAT+ to read the full story…

216

216

Pharmacy Times

MARCH 27, 2024

Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.

59

59

pharmaphorum

JULY 26, 2022

The alliance, billed as the first of its kind in the UK, means that cancer patients will be able to use Big Health apps like Sleepio and Daylight, which aim to treat insomnia and anxiety using cognitive behavioural therapy (CBT) techniques. And in May, Sleepio also became the first digital therapeutic to be recommended by NICE for NHS use.

134

134

Pharmaceutical Technology

MARCH 6, 2023

Incannex Healthcare has collaborated with New Jersey-based pharma company Catalent for the development and manufacturing of a cGMP-grade psilocybin drug product for clinical trials and potential commercial use. The latest development follows an internal analysis of the preliminary results of the Phase II PsiGAD clinical trial.

Drug Development 105

Drug Development 105

The Thyroid Pharmacist

MARCH 31, 2023

Anxiety was one of the most challenging and disempowering symptoms I experienced when I was first diagnosed with Hashimoto’s. I had always been an outspoken, level-headed and calm person, but sometime in 2005, something called “new-onset anxiety” rocked my world. I’ll cover: Do your symptoms indicate you have anxiety?

Immunity 105

Immunity Immunization Dosage Documentation 105

Pharmaceutical Technology

MARCH 18, 2024

Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III for Generalized Anxiety Disorder (GAD).

40

40

Med Ed 101

MAY 31, 2023

Buspirone is an anti-anxiety medication that can be used for chronic management. I’ll outline some of the most important clinical pearls and share some anecdotal education in this blog post. The Good – Buspirone Clinical Pearls Buspirone is well tolerated which is a nice advantage.

52

52

pharmaphorum

DECEMBER 14, 2022

BehaVR is working on VR-enabled DTx for anxiety, stress, pain, and addiction, based on biometrics and machine learning, and these will complement OxfordVR’s pipeline led by gameChange , a virtual psychological therapy designed to provide active coaching to people with psychosis to help them manage anxieties associated with day-to-day life.

104

104

Pharmaceutical Technology

JANUARY 22, 2024

Repurposed Drugs is under clinical development by Luminous Mind and currently in Phase I for Anxiety Disorders.

40

40

Pharmaceutical Technology

JANUARY 22, 2024

Repurposed Drugs is under clinical development by Luminous Mind and currently in Phase I for Anxiety Disorders.

40

40

Pharmaceutical Technology

FEBRUARY 3, 2023

Under the deal, Karuna will have an exclusive worldwide licence for the development, manufacturing, and commercialisation of multiple Goldfinch Bio’s TRPC4/5 candidates, including GFB-887, the lead clinical-stage candidate. In preclinical models of mood and anxiety disorders, GFB-887 showed compelling benefits.

52

52

European Pharmaceutical Review

SEPTEMBER 20, 2022

Zuranolone is an investigational oral 14-day treatment under clinical development for adult patients with MDD and postpartum depression. Zuranolone was generally well-tolerated with a safety profile consistent with prior clinical studies.

Labelling 89

Labelling 89

Med Ed 101

OCTOBER 11, 2023

In this article, we are going to share some of the most clinically important similarities and differences when comparing midazolam versus lorazepam. Both medications are part of the benzodiazepine class and have effects such as sedation, hypnosis, decreased anxiety, amnesia, muscle relaxation, and anticonvulsant effects.

52

52

pharmaphorum

DECEMBER 8, 2021

The company has developed a an individually tailored immersive VR platform that it uses to deliver clinical hypnosis techniques to alleviate chronic pain, anxiety and discomfort during medical procedures like surgery. for its digital sedative for pain, anxiety appeared first on. million ($5.1 The post HypnoVR raises €4.5m

Hospitals 98

Hospitals 98

pharmaphorum

SEPTEMBER 23, 2022

On Tuesday, Curebase announced a three-year clinical trial partnership with Meru Health, the study looking at the effectiveness of the latter’s 12-week treatment program, developed to reduce depression in primary care patients.

57

57

Outsourcing Pharma

SEPTEMBER 28, 2022

Meru Health has tasked decentralized clinical trial (DCT) specialist Curebase with supporting a study of its app-based treatment program for depression, burnout, and anxiety.

52

52

Pharmacy Times

JANUARY 4, 2023

The benefits of physical activity may be greater for children and adolescents with clinical depression or depressive symptoms, who may develop anxiety and other disorders in adulthood.

55

55

pharmaphorum

OCTOBER 14, 2021

UK-based Big Health has passed a digital health milestone after Scotland became the first country to make anxiety and insomnia digital therapeutics available on a national basis. The new arrangement gives them full national coverage.

People Management 102

People Management 102

European Pharmaceutical Review

MARCH 8, 2023

PureTech Health has announced it will advance its oral allopregnanolone candidate LYT-300, for the potential treatment of anxiety and postpartum depression (PPD). A placebo-controlled, Phase IIa, proof-of-concept, social anxiety clinical trial is expected to begin in the first half of 2023.

Labelling 92

Labelling 92

pharmaphorum

OCTOBER 13, 2022

Swedish digital health company Alex Therapeutics has reported encouraging results in a trial of a digital therapeutic (DTx) for anxiety in patients with the respiratory disease idiopathic pulmonary fibrosis (IPF). The post Digital therapeutic cuts IPF-related anxiety by half in pilot study appeared first on.

Labelling 57

Labelling 57

Med Ed 101

MAY 3, 2023

In this Antabuse case study, JE is a 62-year-old male with a history of anxiety, bipolar disorder, alcohol abuse disorder, BPH, hypercholesterolemia, Afib, HTN, and GERD.

52

52

pharmaphorum

SEPTEMBER 8, 2022

Asking patients with chronic conditions to regularly inject themselves can be challenging, causing needle anxiety and worry that they may not carry out the procedure correctly, which can reduce compliance. The post Ypsomed brings Sidekick on board to fight self-injection anxiety appeared first on.

Communication 104

Communication 104

Pharmafile

APRIL 14, 2023

Published date: 14/04/2023 Summary: – Primary endpoint achieved statistically significant improvement in MDD symptoms – – Confirmation of activity of lysergide in brain health disorders with direct relevance to MindMed’s MM-120 program in Generalized Anxiety Disorder (GAD) – – Data presented on April 14, 2023 in Basel, Switzerland – NEW YORK, April (..)

52

52

pharmaphorum

APRIL 22, 2022

Sweden’s Vicore Pharma has started a clinical trial of a digital therapeutic (DTx) intended to relieve anxiety in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and progressive respiratory disease with no curative treatment.

Immunity 57

Immunity Immunization 57

European Pharmaceutical Review

DECEMBER 15, 2022

The primary endpoint in both trials evaluated the proportion of patients with clinically meaningful improvement in itch from baseline (measured by a ≥4-point reduction in Worst-Itch Numeric Rating Scale [WI-NRS] on a 0-10 scale) at 24 and 12 weeks, respectively. Phase III trial data that formed the basis of the EC’s approval.

Hospitals 84

Hospitals 84

pharmaphorum

SEPTEMBER 7, 2021

A study has shown that people with anxiety or depression who used a digital therapeutic (DTx) for insomnia alongside psychological therapy, had better improvement in their mental health than those receiving therapy on its own.

62

62

pharmaphorum

MARCH 4, 2021

In some patients the fear and anxiety can get so acute that the only way to proceed is with sedation. The company says that thanks to the soothing environment – with sound, video projection and dynamic lighting – surveys show that 76% of clinical staff reported reduced tension in their patients, while reduced fear was reported by 71%.

Hospitals 131

Hospitals 131

pharmaphorum

SEPTEMBER 9, 2020

A company that has developed a digital treatment for pain and anxiety – Belgium-based Oncomfort – has raised €10 million in first-round financing that will be used to fund international growth. The medical community has discovered the advantages and potential of digital sedation to relieve pain and anxiety without medication,” he added.

78

78

European Pharmaceutical Review

DECEMBER 13, 2022

North American psychedelic drug developers Mindset, PharmAla, Mydecine and Psyence have signed with clinical research organisation (CRO) Clerkenwell Health to trial therapies for mental health conditions, in London, UK, to benefit from the country’s swift drug regulatory process.

Compounding 101

Compounding Drug Development 101

Pharmacy Times

SEPTEMBER 22, 2022

Research suggests that acupuncture may be able to clinically reduce symptoms of anxiety in this patient population.

49

49

pharmaphorum

AUGUST 26, 2021

A recent study also found that nearly half of adults in the US reported symptoms of anxiety or depression during the pandemic. Virtual tools are one way to address that problem, and Headspace and Ginger both point to clinical studies showing that their approaches can have a benefit.

120

120

pharmaphorum

AUGUST 6, 2021

Patient enrollment is a common issue across many therapeutic areas in clinical research. Psychiatric disorders have historically had great difficulty onboarding and retaining patients for clinical trials. In terms of poor enrolment, clinical trials investigating psychotic disorders like schizophrenia face a particular dilemma. .

Hospitals 104

Hospitals Communication 104

European Pharmaceutical Review

JUNE 26, 2023

US Food and Drug Administration (FDA) has published its first draft guidance presenting considerations to the pharmaceutical industry for designing clinical trials for psychedelic drugs. The draft guidance is intended to advise researchers on aspects such as clinical study design as they develop medications that contain psychedelics.

Controlled Substances 86

Controlled Substances Drug Development 86

pharmaphorum

NOVEMBER 25, 2021

The company’s artificial intelligence-powered software uses cognitive behavioural therapy techniques to help patients suffering from a range of mental health issues, including depression and anxiety. The cash injection is earmarked for getting the DTx products through regulatory approvals in the UK and US, and building commercial teams.

70

70

pharmaphorum

APRIL 25, 2022

BehaVR and Sumitomo signed a potential $140 million deal to create virtual reality (VR) therapies to treat social anxiety disorder, generalised anxiety disorder, and major depressive disorder. “We had the subject matter expertise in those clinical areas, and BehaVR clearly had the technical expertise.

104

104

pharmaphorum

MAY 6, 2022

A digital therapeutic (DTx) developed to help people suffering from insomnia has been shown to improve sleep and mental health in people recovering from a stroke in a clinical trial. The use of the Sleepio app improved sleep quality in 48% of patients enrolled into the study, which was conducted with the University of Oxford.

52

52

pharmaphorum

SEPTEMBER 23, 2021

A study has found that listening to a specially composed music track can achieve “clinically significant” reductions in pain intensity and unpleasantness, according to the researchers behind the work. Image by whoalice-moore from Pixabay.

136

136